FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007421966> ?p ?o ?g. }

• W2007421966 abstract "Glycogen synthase kinase‐3 (GSK‐3) is a constitutively active protein kinase that plays a role in diverse signaling pathways. Initially described as a regulator of glycogen synthesis and metabolism, GSK‐3 is now known to play a central role in a variety of cellular functions ranging from maintenance of stem cell function to regulation of cell cycle and apoptosis. In mammals, there are two highly homologous isoforms of GSK‐3 (GSK‐3α and GSK‐3β) which share substrate specificity and functional properties. GSK3β is one of the key components of the β‐catenin destruction complex and phosphorylation of β‐catenin by GSK‐3 targets the substrate protein for ubiquitylation and proteosomal destruction ‐ conversely, inhibition of GSK‐3β activity results in loss of phosphorylation sites and stabilization of β‐catenin in the cellular cytoplasm and nucleus. GSK‐3 expression and/or activity have been reported to be elevated in multiple tumor types, including pancreatic, gastric and colorectal carcinomas. Equally important, inhibition of GSK‐3 expression in colorectal tumor cell lines via specific siRNAs induced apoptosis and attenuated the proliferation of tumor cells. Together, these findings suggest that GSK‐3 inhibitors may represent a new class of therapeutic agents against colorectal cancer. LY‐GSK‐3i is a novel, potent and selective ATP competitive inhibitor of both isoforms of GSK‐3. In vitro, LY potently inhibits the enzymatic activity of GSK‐3α and GSK‐3β with IC50s of 1.5 nM and 0.9 nM, respectively. Pharmacologic activity of other GSK‐3 inhibitors in the literature against cancer is not clear. LY‐GSK‐3i did not evidence useful antitumor activity in its own right against colorectal, ovarian or non‐small cell lung (NSCL) tumor lines. However, when combined with different chemotherapeutic agents, LY was found to potentiate their pro‐apoptotic activity. LY‐GSK‐3i was shown to significantly potentiate caspase‐3 activation when combined cisplatin in HCT‐116 and Colo‐205 colorectal carcinoma lines. Enhancement of caspase‐3 activity was also observed when LY‐GSK‐3i was combined with 5‐fluorouracyl (5‐FU) in HCT‐116 cells. In order to explore the potential of LY‐GSK‐3i in other tumor types, we assessed the pro‐apoptotic activity of the LY/cisplatin combination against ovarian (A2780) and lung (A549 and NCI‐H460) cell lines. In all cases, LY‐GSK‐3i was shown to significantly elevate caspase‐3 activity when compared to cisplatin alone. In vivo, administration of a single dose of LY‐GSK‐3i to xenograft‐bearing mice lead to a time‐and dose‐dependent accumulation of the substrate protein ‐catenin in tumor tissues. In vivo xenograft growth studies revealed that administration of 5 mg/kg LY‐GSK‐3i in combination with cisplatin, given every 7 or 14 days, was sufficient to significantly improve the efficacy as compared to cisplatin alone given at the same intervals. Together, our findings provide evidence for the potential therapeutic utility of GSK‐3 inhibitors for the treatment of cancer. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C211." @default.
• W2007421966 created "2016-06-24" @default.
• W2007421966 creator A5005164780 @default.
• W2007421966 creator A5014341579 @default.
• W2007421966 creator A5042018889 @default.
• W2007421966 creator A5050854363 @default.
• W2007421966 creator A5067708666 @default.
• W2007421966 creator A5071901078 @default.
• W2007421966 creator A5073290437 @default.
• W2007421966 date "2009-12-10" @default.
• W2007421966 modified "2023-09-25" @default.
• W2007421966 title "Abstract C211: Therapeutic utility of GSK‐3 inhibitors for the treatment of cancer" @default.
• W2007421966 doi "https://doi.org/10.1158/1535-7163.targ-09-c211" @default.
• W2007421966 hasPublicationYear "2009" @default.
• W2007421966 type Work @default.
• W2007421966 sameAs 2007421966 @default.
• W2007421966 citedByCount "0" @default.
• W2007421966 crossrefType "proceedings-article" @default.
• W2007421966 hasAuthorship W2007421966A5005164780 @default.
• W2007421966 hasAuthorship W2007421966A5014341579 @default.
• W2007421966 hasAuthorship W2007421966A5042018889 @default.
• W2007421966 hasAuthorship W2007421966A5050854363 @default.
• W2007421966 hasAuthorship W2007421966A5067708666 @default.
• W2007421966 hasAuthorship W2007421966A5071901078 @default.
• W2007421966 hasAuthorship W2007421966A5073290437 @default.
• W2007421966 hasConcept C104629339 @default.
• W2007421966 hasConcept C11960822 @default.
• W2007421966 hasConcept C182996813 @default.
• W2007421966 hasConcept C184235292 @default.
• W2007421966 hasConcept C185592680 @default.
• W2007421966 hasConcept C190283241 @default.
• W2007421966 hasConcept C192118531 @default.
• W2007421966 hasConcept C22615655 @default.
• W2007421966 hasConcept C29537977 @default.
• W2007421966 hasConcept C502942594 @default.
• W2007421966 hasConcept C54009773 @default.
• W2007421966 hasConcept C54355233 @default.
• W2007421966 hasConcept C55493867 @default.
• W2007421966 hasConcept C62112901 @default.
• W2007421966 hasConcept C81885089 @default.
• W2007421966 hasConcept C86803240 @default.
• W2007421966 hasConcept C95444343 @default.
• W2007421966 hasConceptScore W2007421966C104629339 @default.
• W2007421966 hasConceptScore W2007421966C11960822 @default.
• W2007421966 hasConceptScore W2007421966C182996813 @default.
• W2007421966 hasConceptScore W2007421966C184235292 @default.
• W2007421966 hasConceptScore W2007421966C185592680 @default.
• W2007421966 hasConceptScore W2007421966C190283241 @default.
• W2007421966 hasConceptScore W2007421966C192118531 @default.
• W2007421966 hasConceptScore W2007421966C22615655 @default.
• W2007421966 hasConceptScore W2007421966C29537977 @default.
• W2007421966 hasConceptScore W2007421966C502942594 @default.
• W2007421966 hasConceptScore W2007421966C54009773 @default.
• W2007421966 hasConceptScore W2007421966C54355233 @default.
• W2007421966 hasConceptScore W2007421966C55493867 @default.
• W2007421966 hasConceptScore W2007421966C62112901 @default.
• W2007421966 hasConceptScore W2007421966C81885089 @default.
• W2007421966 hasConceptScore W2007421966C86803240 @default.
• W2007421966 hasConceptScore W2007421966C95444343 @default.
• W2007421966 hasLocation W20074219661 @default.
• W2007421966 hasOpenAccess W2007421966 @default.
• W2007421966 hasPrimaryLocation W20074219661 @default.
• W2007421966 hasRelatedWork W1974760106 @default.
• W2007421966 hasRelatedWork W1991649432 @default.
• W2007421966 hasRelatedWork W2020105159 @default.
• W2007421966 hasRelatedWork W2036978461 @default.
• W2007421966 hasRelatedWork W2050206485 @default.
• W2007421966 hasRelatedWork W2071473674 @default.
• W2007421966 hasRelatedWork W2077061070 @default.
• W2007421966 hasRelatedWork W2105627373 @default.
• W2007421966 hasRelatedWork W2126395872 @default.
• W2007421966 hasRelatedWork W2150622242 @default.
• W2007421966 hasRelatedWork W2318594458 @default.
• W2007421966 hasRelatedWork W2470075301 @default.
• W2007421966 hasRelatedWork W2538213603 @default.
• W2007421966 hasRelatedWork W2909379025 @default.
• W2007421966 hasRelatedWork W2918006755 @default.
• W2007421966 hasRelatedWork W2947284273 @default.
• W2007421966 hasRelatedWork W3011054134 @default.
• W2007421966 hasRelatedWork W3183248372 @default.
• W2007421966 hasRelatedWork W2924435608 @default.
• W2007421966 hasRelatedWork W2967729922 @default.
• W2007421966 isParatext "false" @default.
• W2007421966 isRetracted "false" @default.
• W2007421966 magId "2007421966" @default.
• W2007421966 workType "article" @default.